|
|
|
Volumn 13, Issue 10, 2010, Pages 698-700
|
|
Empowered Antibody Therapies - IBC conference
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALBINTERFERON ALPHA2B;
ANTIBODY;
BISPECIFIC ANTIBODY;
BLINATUMOMAB;
CATUMAXOMAB;
CD3 ANTIBODY;
EKTOMUN;
ERTUMAXOMAB;
FBT A05;
GLYCOPROTEIN GP 100;
IMMUNOGLOBULIN;
LYMPHOMUN;
MT 103;
RANPIRNASE;
REMOVAB;
RITUXIMAB;
SMALL INTERFERING RNA;
UNCLASSIFIED DRUG;
ACUTE LYMPHOBLASTIC LEUKEMIA;
ANTIBODY RESPONSE;
ASCITES;
AUTOIMMUNE DISEASE;
BREAST CANCER;
CANCER CELL CULTURE;
CANCER SURVIVAL;
CLINICAL TRIAL;
CONFERENCE PAPER;
CONTINUOUS INFUSION;
CYTOTOXICITY;
DRUG DOSE ESCALATION;
DRUG FEVER;
DRUG INDUCED HEADACHE;
DRUG WITHDRAWAL;
HUMAN;
IMMUNE RESPONSE;
IMMUNOTHERAPY;
LUNG CANCER;
LYMPHOCYTOPENIA;
LYMPHOMA;
LYMPHOMA CELL;
MELANOMA;
MULTIPLE CYCLE TREATMENT;
NEOPLASM;
NONHODGKIN LYMPHOMA;
NONHUMAN;
PANCREAS CANCER;
PROSTATE CANCER;
PROTEIN PROTEIN INTERACTION;
T LYMPHOCYTE;
UTERINE CERVIX CANCER;
ANIMALS;
ANTIBODIES;
ANTIBODIES, BISPECIFIC;
CLINICAL TRIALS, PHASE II AS TOPIC;
DRUGS, INVESTIGATIONAL;
HUMANS;
IMMUNIZATION, PASSIVE;
MICE;
MOLECULAR TARGETED THERAPY;
RATS;
|
|
EID: 77957743966
PISSN: 13697056
EISSN: None
Source Type: Journal
DOI: None Document Type: Conference Paper |
|
Times cited : (1)
|
|
References (0)
|
